Table 3.
Timing of risk reducing contralateral mastectomy (RRCM) in women with BRCA-associated breast cancer
| RRCM after breast cancer diagnosis | Breast cancer patients who had a DNA test before diagnosis (predictive) (n = 53) | Breast cancer patients who had a DNA test after diagnosis (diagnostic) (n = 127) | ||||
|---|---|---|---|---|---|---|
| Breast cancer diagnosis 1995–2000 | Breast cancer diagnosis 2001–2009 | p | Breast cancer diagnosis 1995–2000 | Breast cancer diagnosis 2001–2009 | p | |
| Age at RRCM in years | 0.62 | 0.55 | ||||
| Mean (SD) | 42.1 (7.9) | 44.2 (10.0) | 41.8 (7.8) | 40.3 (7.7) | ||
| Median (range) | 41.5 (25–53) | 45.0 (27–71) | 41.0 (22–62) | 40.5 (25–54) | ||
| Median time in months between diagnosis and RRCMa | 2 | 15 | 0.14 | 77 | 27 | 0.05 |
|
RRCM 2001–2009 versus 1995–2000 HR (95 % CI)b |
0.73 (0.36–1.48) | 1.72 (0.91–3.27) | ||||
Only for patients with information on whether having undergone RRCM (from Erasmus MC Cancer Institute, NKI and UMCU), who had unilateral breast cancer. Immediate and delayed RRCM were analyzed together
RRCM risk reducing contralateral mastectomy
aKaplan–Meier analyses for predictive and diagnostic patients
bSeparate Cox regression models for predictive and diagnostic patients, adjusted for age at diagnosis, nodal status, and chemotherapy